ARCHIVES

NCI Initiatives: Two RFAs Planned In New Technologies for Molecular Biology

This article is from The Cancer Letter archive.

Vol. 22 No. 47 | December 6, 1996

Download PDF Visit The Full Archive

Related Articles

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

October 20, 2006

Oblimersen Combination Improves CLL Survival

December 28, 2007

In Brief: Baltimore Resigns as Rockefeller President; Perry Named Medical Director At Ellis Fischel

December 13, 1991

Six Institutions Get Awards For LAK-IL-2 Trials

February 7, 1986

GAO: FDA Data On Drug Shortages Inadequate

February 21, 2014

FDA Committee nixes Combination Guidelines, Okays New NDA Policy

January 21, 1977